Thyroid
Thyroid cancer incidence plateaued during 2010s after rising from 1975 to 2009
After rising over a 35-year period, thyroid cancer incidence in the U.S. plateaued from 2010 to 2019, according to findings published in The Lancet Diabetes & Endocrinology.
VIDEO: Collaborative effort needed for managing Graves’ disease during pregnancy
In this Healio Video Exclusive, Nicole Gomez, MD, speaks with Caroline T. Nguyen, MD, about managing Graves’ disease during pregnancy.
Increased screening may lead to higher thyroid cancer risk after GLP-1 initiation
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP-1 initiation, researchers reported.
The changing landscape of endocrinology: GLP-1s, new diabetes technology and more
The field of endocrinology saw many advancements in 2024 and more developments and innovations are anticipated in 2025.
Endocrinology Drug and Device Update
In a review of the 2024 milestones, Healio | Endocrine Today compiled a list of drugs and devices related to the field that were newly approved, cleared or had label or indication changes. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omission. Appearance of a drug or device does not constitute any endorsement by Healio | Endocrine Today, its editors, publishers or editorial board. — The Editors
Timing of mild maternal hypothyroidism ‘pivotal’ for predicting pregnancy outcomes
Third-trimester subclinical hypothyroidism and first- and third-trimester isolated maternal hypothyroxinemia were tied to various adverse pregnancy outcomes, highlighting the importance of trimester-specific thyroid function evaluations.
Once-weekly batoclimab lowers immunoglobulin for adults with uncontrolled Graves’ disease
Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant.
Teprotumumab does not raise rates of hearing-related adverse events in thyroid eye disease
Adults receiving teprotumumab for the treatment of thyroid eye disease experience a similar number of hearing-related adverse events as those not treated with teprotumumab, according to new data.
Progression to overt hypothyroidism more likely with subclinical disease during pregnancy
Women with subclinical hypothyroidism during the first half of pregnancy are more likely to develop overt hypothyroidism 5 years after delivery than women with hypothyroxinemia, according to a study published in Thyroid.
Thyroid autoimmunity may occur in first few years of life for some children
The presence of thyroid autoantibodies may be detected as early as age 10 months for children, and those positive for both thyroid peroxidase and thyroglobulin autoantibodies have a higher risk for thyroid disease, according to study data.